Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Licenses System Biosciences' Exosome Isolation Technology

NEW YORK (GenomeWeb) – System Biosciences said today that Qiagen has signed a non-exclusive, worldwide license for SBI's ExoQuick exosome isolation technology for research use.

Qiagen intends to use the technology in its precipitation-based miRcury Exosome Kits, complementing its spin column-based exoEasy and exoRNeasy products.

"Qiagen's license demonstrates the value of ExoQuick technology for high-throughput, scalable isolation of exosomes from a range of biofluid samples," Jake Lesnik, vice president of commercial development at SBI, said in a statement. "The license agreement also demonstrates SBI's commitment to protecting its proprietary ExoQuick technology, which is used by thousands of researchers globally for fast and efficient exosome isolation."

Besides ExoQuick, Palo Alto, California-based SBI provides several exosome research tools and services including ExoFBS, ExoFlow, Exo-fect, and ExoGlow technologies, as well as Exo-NGS and ExoMS services for exosomal RNA-seq and proteomics analysis, respectively.

The Scan

Close Panel Vote on Califf Nomination

The New York Times reports there was a close committee vote to advance the nomination of Robert Califf to lead the US Food and Drug Administration to the full Senate.

Task Force Reports on Scientific Integrity

Nature News writes that that a new task force report recommends that the US establish a cross-agency scientific integrity council.

Across the Hall

Genetic testing, closed-circuit cameras, and more show how a traveler, without any contact, infected others at a New Zealand quarantine facility, CNN reports.

Science Paper Examines Influence of Chromatin Modifications on Obsessive-Compulsive Disorder

In Science this week: genes regulating chromatin modification may contribute to OCD risk.